Literature DB >> 11642679

The role of the Fas/Fas ligand system in estrogen-induced thymic alteration.

G Mor1, A Muñoz, R Redlinger, I Silva, J Song, C Lim, F Kohen.   

Abstract

PROBLEM: Estrogen induces atrophy in the thymus by an unknown mechanism. Since the Fas/FasL system is one of the main pathways in T cell apoptosis, we tested the hypothesis that estrogen-induced thymic atrophy is mediated by the Fas/FasL system. METHODS OF STUDY: In vivo experiments were done using ovariectomized female rats treated with estrogen or saline. In vitro experiments were performed using isolated thymocytes. Estrogen receptor (ER) alpha and beta expression was characterized using flow cytometry, RT-PCR and immunofluorescence. Fas and FasL mRNA and protein expression was evaluated using RT-PCR and Western blot analysis respectively.
RESULTS: ERalpha and ERbeta are present in thymocytes and stromal cells. ER expression is mainly localized in the Double Positive CD4+CD8+ thymocytes. Estrogen treatment decreases thymus size and increase FasL expression.
CONCLUSION: CD4+CD8+ thymocytes and thymic stroma cells express ERalpha and ERbeta. In vivo and in vitro we showed that estrogen treatment increases FasL expression while decreasing thymus cell number. These findings support the hypothesis that estrogen-induced thymic atrophy occurs as a result of apoptosis and is mediated by estrogen-induced FasL expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11642679     DOI: 10.1034/j.1600-0897.2001.d01-16.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  9 in total

Review 1.  Clinical strategies to enhance T cell reconstitution.

Authors:  Gabrielle L Goldberg; Johannes L Zakrzewski; Miguel A Perales; Marcel R M van den Brink
Journal:  Semin Immunol       Date:  2007-10-26       Impact factor: 11.130

2.  Impaired estrogen signaling underlies regulatory T cell loss-of-function in the chronically inflamed intestine.

Authors:  Wendy A Goodman; Sarah M Bedoyan; Hannah L Havran; Brian Richardson; Mark J Cameron; Theresa T Pizarro
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-06       Impact factor: 11.205

3.  Differential estrogen receptor expression in autoimmune myasthenia gravis.

Authors:  Patrice Nancy; Sonia Berrih-Aknin
Journal:  Endocrinology       Date:  2005-01-20       Impact factor: 4.736

4.  Methoxychlor metabolite HPTE alters viability and differentiation of embryonic thymocytes from C57BL/6 mice.

Authors:  Lucie Leung-Gurung; Priscilla Escalante Cobb; Faraj Mourad; Cristina Zambrano; Zachary Muscato; Victoria Sanchez; Kanya Godde; Christine Broussard
Journal:  J Immunotoxicol       Date:  2018-12       Impact factor: 3.000

5.  Subtype specific estrogen receptor action protects against changes in MMP-2 activation in mouse retinal pigmented epithelial cells.

Authors:  Sharon Elliot; Paola Catanuto; Pedro Fernandez; Diego Espinosa-Heidmann; Michael Karl; Kenneth Korach; Scott W Cousins
Journal:  Exp Eye Res       Date:  2008-01-17       Impact factor: 3.467

Review 6.  B lymphocytes and systemic lupus erythematosus.

Authors:  Lisa G Criscione; David S Pisetsky
Journal:  Curr Rheumatol Rep       Date:  2003-08       Impact factor: 4.592

7.  Thymocyte Differentiation is Regulated by a Change in Estradiol Levels during the Estrous Cycle in Mouse.

Authors:  Hyojin Lee; Heejung Kim; Yiwa Chung; Jinhee Kim; Hyunwon Yang
Journal:  Dev Reprod       Date:  2013-12

8.  Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer.

Authors:  Toralf Reimer; Dirk Koczan; Heiner Müller; Klaus Friese; Hans-Jürgen Thiesen; Bernd Gerber
Journal:  Breast Cancer Res       Date:  2002-06-21       Impact factor: 6.466

Review 9.  The Immune System Is a Natural Target for Estrogen Action: Opposing Effects of Estrogen in Two Prototypical Autoimmune Diseases.

Authors:  Deena Khan; S Ansar Ahmed
Journal:  Front Immunol       Date:  2016-01-06       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.